Clinical Trial Update: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Fx-1006A in non-V30M transthyretin amyloidosis with polyneuropathy evaluated for transthyretin stabilization and clinical outcomes; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Polyneuropathy

Drugs mentioned

• Fx-1006A

Snippet

Sponsor: Pfizer | Conditions: Transthyretin-associated Amyloidosis With Polyneuropathy | Phase 2 | Status: COMPLETED | Results posted: 2012-12-17